Smartwatches, rings, adhesive patches, and smart clothing - monitoring your health is no longer limited to clinics and hospitals. Wearable devices have evolved fast. It wasn't long ago when applications for counting steps and monitoring sleep quality felt ingenious. Still, it did not take us long to develop technologies that do everything from collecting medical-grade signals (ECG, photoplethysmography (PPG), continuous glucose monitoring (CGM), motion/respiration) to aiding in diagnosis, remote monitoring, and treatment optimization. Several critical regulatory milestones and clinical studies in 2024-2025 indicate that wearables are entering mainstream clinical care. Let us look at some jaw-dropping innovations.
Multiple studies and regulatory reviews in 2024-2025 highlight progress toward clinically useful cuffless blood-pressure measurement (PPG-based and cuff-oscillometric smartwatch approaches). Cuffless tech is promising for screening and ambulatory trends, though many systems require clinic confirmation and further validation for treatment decisions. [3]
Large clinical evaluations show modern smartwatches and algorithm pipelines achieve high sensitivity and specificity for AF detection in many populations, making consumer wearables a useful triage and screening tool when integrated with clinical workflows. [4]
Wearable ECG patches are being used as prescription tools for prolonged rhythm monitoring outside hospital settings, improving arrhythmia diagnosis rates. [2]
The FDA’s Digital Health Center of Excellence and curated lists of sensor-based digital health technologies reflect growing regulatory attention and pathways for wearable medical devices to be authorized and integrated into care. [5]
Remote arrhythmia surveillance
Prescription ECG patches and smartwatch ECG recordings help capture intermittent palpitations, syncope, or cryptogenic stroke workups. [6]
Diabetes management and population screening
OTC CGMs and prescription CGMs provide continuous glucose profiles for dose optimization, lifestyle counseling and risk stratification.
Blood-pressure trend monitoring
Smartwatch cuff-oscillometric devices and validated home cuffless systems help detect undiagnosed hypertension and track patterns (day/night), though clinic cuff confirmation remains recommended.
Activity and recovery monitoring
Wearables quantify mobility and sleep to guide rehabilitation, perioperative recovery and chronic disease management.
Continuous or frequent sampling captures intermittent events missed in the clinic. [6]
Improved patient engagement, many users act on data (med adherence, lifestyle).[7]
Validation matters. Not all consumer devices are clinically validated; clinicians should rely on FDA-cleared products or peer-reviewed accuracy studies when making decisions.
False positives/negatives. Screening tools can generate noise, for example, inconclusive AF readings or inaccurate cuffless BP in some populations. Therefore, these require confirmatory testing.
Data overload and workflow integration. Large volumes of longitudinal data need clinical pathways, algorithmic triage, and Electronic Health Record integration to be actionable.
Cuffless BP moves toward clinical readiness with hybrid validation frameworks and smartwatch cuff-oscillometric approaches.
AI-driven interpretation embedded on device (local edge AI) to pre-triage signals and preserve privacy.[9]
Multimodal wearables (ECG, PPG, motion, temperature) for richer phenotyping and earlier disease detection.[7]
Regulatory clarity — more device clearances and guidance for real-world evidence will lower barriers for clinical adoption.
U.S. Food and Drug Administration. “FDA Clears First Over-the-Counter Continuous Glucose Monitor.” March 5, 2024. Accessed November 29, 2025. https://www.fda.gov/news-events/press-announcements/fda-clears-first-over-counter-continuous-glucose-monitor
Hypertension Research (Nature) Stergiou, George S., Ariadni Menti, Dimitrios Mariglis, and Anastasios Kollias. “The Quest for Accurate Wearable Blood Pressure Monitors.” Hypertension Research, published November 5, 2025. https://www.nature.com/articles/s41440-025-02410-w
JACC: Advances Barrera, Nelson, Maria Solorzano, Yomary Jimenez, Yevhen Kushnir, Francisco Gallegos-Koyner, and Guilherme Dagostin de Carvalho. “Accuracy of Smartwatches in the Detection of Atrial Fibrillation: A Systematic Review and Diagnostic Meta-Analysis.” JACC: Advances 4, no. 11_Part_1 (October 28, 2025). https://www.jacc.org/doi/10.1016/j.jacadv.2025.102133
U.S. Food and Drug Administration. “Medical Devices that Incorporate Sensor-based Digital Health Technology.” July 2025. Accessed November 29, 2025. https://www.fda.gov/medical-devices/digital-health-center-excellence/medical-devices-incorporate-sensor-based-digital-health-technology
JMIR Mhealth and Uhealth (PMC) Kang, Harjeevan Singh, and Mark Exworthy. “Wearing the Future—Wearables to Empower Users to Take Greater Responsibility for Their Health and Care: Scoping Review.” JMIR Mhealth and Uhealth 10, no. 7 (July 13, 2022): e35684. https://pmc.ncbi.nlm.nih.gov/articles/PMC9330198/
MSM
